Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
DISHMAN PHARMA | ASTRAZENECA PHARMA | DISHMAN PHARMA/ ASTRAZENECA PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 128.6 | 19.5% | View Chart |
P/BV | x | 3.3 | 39.4 | 8.5% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
ASTRAZENECA PHARMA Mar-18 |
DISHMAN PHARMA/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 1,278 | 29.3% | |
Low | Rs | 129 | 883 | 14.6% | |
Sales per share (Unadj.) | Rs | 197.8 | 228.4 | 86.6% | |
Earnings per share (Unadj.) | Rs | 21.2 | 10.4 | 204.6% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 16.3 | 213.5% | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 179.9 | 98.8 | 182.1% | |
Shares outstanding (eoy) | m | 80.69 | 25.00 | 322.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 4.7 | 26.9% | |
Avg P/E ratio | x | 11.9 | 104.2 | 11.4% | |
P/CF ratio (eoy) | x | 7.2 | 66.4 | 10.9% | |
Price / Book Value ratio | x | 1.4 | 10.9 | 12.8% | |
Dividend payout | % | 9.4 | 0 | - | |
Avg Mkt Cap | Rs m | 20,306 | 27,008 | 75.2% | |
No. of employees | `000 | 0.8 | 1.4 | 61.1% | |
Total wages/salary | Rs m | 5,355 | 1,535 | 348.8% | |
Avg. sales/employee | Rs Th | 19,252.7 | 4,210.9 | 457.2% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,132.2 | 570.5% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 191.1 | 1,080.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 5,710 | 279.5% | |
Other income | Rs m | 265 | 123 | 216.7% | |
Total revenues | Rs m | 16,226 | 5,833 | 278.2% | |
Gross profit | Rs m | 4,103 | 463 | 886.4% | |
Depreciation | Rs m | 1,091 | 147 | 739.9% | |
Interest | Rs m | 944 | 0 | - | |
Profit before tax | Rs m | 2,334 | 438 | 532.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 179 | 348.6% | |
Profit after tax | Rs m | 1,711 | 259 | 660.4% | |
Gross profit margin | % | 25.7 | 8.1 | 317.1% | |
Effective tax rate | % | 26.7 | 40.8 | 65.4% | |
Net profit margin | % | 10.7 | 4.5 | 236.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 3,209 | 343.3% | |
Current liabilities | Rs m | 9,517 | 2,070 | 459.9% | |
Net working cap to sales | % | 9.4 | 20.0 | 47.1% | |
Current ratio | x | 1.2 | 1.6 | 74.7% | |
Inventory Days | Days | 110 | 72 | 152.7% | |
Debtors Days | Days | 35 | 35 | 99.8% | |
Net fixed assets | Rs m | 16,304 | 790 | 2,063.0% | |
Share capital | Rs m | 161 | 50 | 322.8% | |
"Free" reserves | Rs m | 12,907 | 2,419 | 533.5% | |
Net worth | Rs m | 14,516 | 2,469 | 587.8% | |
Long term debt | Rs m | 4,189 | 0 | - | |
Total assets | Rs m | 29,805 | 4,605 | 647.2% | |
Interest coverage | x | 3.5 | NM | - | |
Debt to equity ratio | x | 0.3 | 0 | - | |
Sales to assets ratio | x | 0.5 | 1.2 | 43.2% | |
Return on assets | % | 8.9 | 5.6 | 158.4% | |
Return on equity | % | 11.8 | 10.5 | 112.3% | |
Return on capital | % | 17.5 | 17.7 | 98.8% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 300 | 1,653.0% | |
Fx outflow | Rs m | 697 | 2,015 | 34.6% | |
Net fx | Rs m | 4,255 | -1,715 | -248.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 88 | 3,170.0% | |
From Investments | Rs m | -1,529 | -94 | 1,633.4% | |
From Financial Activity | Rs m | -941 | NA | - | |
Net Cashflow | Rs m | 316 | -6 | -5,550.9% |
Indian Promoters | % | 61.4 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 75.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 0.3 | 1,233.3% | |
FIIs | % | 12.7 | 15.7 | 80.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 9.1 | 242.9% | |
Shareholders | 46,261 | 12,856 | 359.8% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: ORCHID PHARMA WYETH ABBOTT INDIA SUVEN LIFE SCIENCES DR. REDDYS LAB
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Share markets in India are presently trading on a volatile note. The BSE Sensex is trading up by 11 points, flat, at 47,960 levels.
WOCKHARDT share price is trading up by 13% and its current market price is Rs 527. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 12.6%) and ASTRAZENECA PHARMA (up 5.7%). The top losers are GSK PHARMA and ALKEM LABORATORIES (down 0.1%).
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
Those who don't learn from financial history are doomed to lose their money.
More